New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
09:52 EDTLPCNLipocine management to meet with Roth Capital
Meetings to be held in San Diego/Los Angeles on August 6 hosted by Roth Capital.
July 22, 2015
10:01 EDTLPCNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:19 EDTLPCNLipocine initiated with a Buy at Roth Capital
Target $36.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use